Vertex Pharma reports ALYFTREK data. RBC raises target for Vertex Pharma stock to USD 576

Published on 10/12/2026 at 11:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharma stock trades at EUR 455.73 on October 12, 2026 during trading. RBC raised its target from USD 570 to USD 576 and kept Outperform on October 8, 2026.

Key points in brief

Vertex reported October 9 interim ALYFTREK data from children ages 2 to 5.
18 of 48 eligible children discontinued pancreatic enzyme replacement therapy, or 37.50 percent.
RBC raised its Vertex target from USD 570 to USD 576 on October 8, 2026.
Vertex stock was trading at EUR 455.73 at Lang & Schwarz on October 12, 2026.

Schwarzweiß-Reportagefoto einer Wissenschaftlerin am Mikroskop im Labor — Vertex Pharma US92532F1003 dokumentiert eine Forscherin beim Mikroskopieren in dokumentarischer Schwarzweiß-Reportage-Optik im Labor, Illustration mit AI erstellt.

Vertex Pharma (ISIN US92532F1003) reported interim ALYFTREK data on October 9, 2026, while RBC Capital raised its target for Vertex Pharma stock from USD 570 to USD 576 and kept an Outperform rating on October 8, 2026. The ALYFTREK data came from children ages 2 to 5 and showed that 18 of 48 eligible children, or 37.50 percent, discontinued pancreatic enzyme replacement therapy.

ALYFTREK data add a clinical marker

According to Vertex Pharmaceuticals on October 9, 2026, the interim analysis followed at least 48 weeks of treatment. The data showed mean fecal elastase-1 of 239.70 micrograms per gram, an increase of 110.20 micrograms per gram from baseline, with 48.60 percent of children reaching the pancreatic sufficiency threshold.

The result is clinically relevant because pancreatic enzyme replacement therapy is a continuing treatment burden in cystic fibrosis. Vertex said the use of ALYFTREK in children ages 2 to 5 remains investigational, so the 37.50 percent discontinuation rate is a study result rather than an approved label expansion.

RBC target moves to USD 576

Markets Insider reported on October 8, 2026, that RBC Capital lifted its Vertex target from USD 570 to USD 576 while keeping an Outperform rating. The USD 6.00 increase equals 1.05 percent versus the former target.

That target revision gives the stock a fresh analyst reference point ahead of the next financial update. It also leaves the ALYFTREK evidence in its proper frame: the study offers a measurable clinical signal, while the investigational status keeps regulatory interpretation separate from commercial revenue.

Next results date is November 2

Vertex Pharmaceuticals said on October 7, 2026, that it will report third-quarter 2026 financial results on November 2, 2026, after the markets close. The company scheduled its conference call for 4:30 p.m. ET, making the report the next dated corporate event for the stock.

Vertex stock was trading at EUR 455.73 at Lang & Schwarz on October 12, 2026, at 11:02 a.m. CEST. The finance quote for the Nasdaq listing showed a market capitalization of USD 129.5 billion on October 9, 2026, while Vertex Pharmaceuticals operates in the healthcare biotechnology sector.

The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.